ClinicalTrials.gov record
Completed Phase 2 Interventional

The Safety and Effectiveness of Interferon Alfa-2B Plus Didanosine in Patients With Kaposi's Sarcoma

ClinicalTrials.gov ID: NCT00001114

Public ClinicalTrials.gov record NCT00001114. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 5, 2026, 6:24 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Randomized Phase II Trial to Determine the Safety, Tolerance, and Efficacy of Two Doses of Interferon Alfa-2b Combined With Didanosine in Patients With Kaposi's Sarcoma

Study identification

NCT ID
NCT00001114
Recruitment status
Completed
Study type
Interventional
Phase
Phase 2
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Enrollment
90 participants

Conditions and interventions

Interventions

  • Didanosine Drug
  • Interferon alfa-2b Drug

Drug

Eligibility (public fields only)

Age range
12 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Not listed
Primary completion
Not listed
Completion
Feb 29, 2000
Last update posted
Oct 31, 2021

Ends 2000

United States locations

U.S. sites
12
U.S. states
9
U.S. cities
10
Facility City State ZIP Site status
Stanford CRS Palo Alto California 94115
University of Colorado Hospital CRS Aurora Colorado 80262
Northwestern University CRS Chicago Illinois 60611
Rush Univ. Med. Ctr. ACTG CRS Chicago Illinois 60612
Indiana Univ. School of Medicine, Infectious Disease Research Clinic Indianapolis Indiana 46202
Bmc Actg Crs Boston Massachusetts 02118
St. Louis ConnectCare, Infectious Diseases Clinic St Louis Missouri 63112
Washington U CRS St Louis Missouri
SUNY - Buffalo, Erie County Medical Ctr. Buffalo New York 14215
Memorial Sloan-Kettering Cancer Ctr. New York New York 10021
Univ. of Cincinnati CRS Cincinnati Ohio 45267
Hosp. of the Univ. of Pennsylvania CRS Philadelphia Pennsylvania 19104

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 1 non-U.S. site.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00001114, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Oct 31, 2021 · Synced May 5, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT00001114 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →